As the promise of synthetic therapies that are lethal against homozygous MTAP-deleted cancers is dependent on intracellular accumulation of MTA, our data caution against the expedient translation of the MTAP-deletion-targeted precision therapies to the clinic and strongly contend that more research is needed into the fundamental metabolic differences between model systems and primary tumors. This evidence concerns the gene MTAP and cancer.